Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

186.56
-14.3100-7.12%
Volume:3.81M
Turnover:705.84M
Market Cap:39.99B
PE:-20.91
High:199.64
Open:198.51
Low:180.52
Close:200.87
52wk High:224.31
52wk Low:46.16
Shares:214.34M
Float Shares:185.00M
Volume Ratio:2.89
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:15.34
PE(LYR):-31.35

Loading ...

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS
·
Sep 10

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Reuters
·
Sep 10

Revolution Medicines Price Target Raised to $230.00/Share from $215.00 by Stifel

Dow Jones
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Sep 09

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

TIPRANKS
·
Sep 03

NEJM publishes Phase 1/2 clinical data on daraxonrasib

TIPRANKS
·
Sep 03

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire
·
Sep 03

Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

Reuters
·
Sep 03

J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Sep 02

Revolution Medicines Signs Long-Term Headquarters Lease Agreement

TIPRANKS
·
Sep 01

Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE

Simply Wall St.
·
Sep 01

Revolution Medicines is Maintained at Buy by Needham

Dow Jones
·
Aug 31

Ami Fadia Raises RVMD Price Target to $275 on Strong Rasonque U.S. Launch Economics and Robust Oncology Pipeline

TIPRANKS
·
Aug 31

Revolution Medicines, Inc. : Needham Raises Target Price to $275 from $240

THOMSON REUTERS
·
Aug 31

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Reuters
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live
·
Aug 29

Movement Alert|Revolution Medicines, Inc. Falls 5.02% in Regular Trading, Profit-Taking Follows FDA Approval of Pancreatic Cancer Drug

Market Focus
·
Aug 28